PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

GHO Capital and the Vistria Group to acquire Alcami from MDP and Ampersand

GHO Capital Partners, a European specialist investor in global healthcare, and the Vistria Group, a middle-market private investment firm, are to acquire a controlling interest in Alcami Corporation, a pharmaceutical contract development and manufacturing organisation, from funds affiliated with Madison Dearborn Partners (MDP) and Ampersand Capital Partners.

GHO Capital Partners (GHO), a European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm, are to acquire a controlling interest in Alcami Corporation (Alcami), a pharmaceutical contract development and manufacturing organisation (CDMO), from funds affiliated with Madison Dearborn Partners (MDP) and Ampersand Capital Partners (Ampersand).

Headquartered in North Carolina, Alcami has built a strong offering, market position, and reputation in high-growth specialties including drug product manufacturing focusing on sterile fill-finish of both biologics and small molecules; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.

GHO Capital and The Vistria Group will acquire a 50/50 controlling interest in Alcami from funds affiliated with MDP and Ampersand. Ampersand and Alcami Management will reinvest significant equity as part of the acquisition. Financial terms of the transaction have not been disclosed.

Ropes & Gray LLP acted as legal advisor to GHO Capital and The Vistria Group, Jefferies Group LLC and OES acted as buyside financial advisors, McKinsey as commercial diligence advisor, Deloitte as financial and tax due diligence advisor, EY as ESG advisor and Lockton as insurance advisor. Financing provided by credit funds managed by Ares Management, as Administrative Agent and Lead Arranger.

Morgan Stanley is serving as financial advisor and Kirkland & Ellis LLP is serving as legal advisor to Alcami.

The transaction is expected to close by the end of 2022, after customary closing conditions and regulatory approvals.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured